This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A Second Look: Discussing Ionis/GSK Topline Phase 3 B-Well 1 & B-Well 2 Results for Bepirovirsen in Chronic Hepatitis B

Ticker(s): IONS, GSK

Who's the expert?

Institution: MissionGH

  • Gastroenterologist in private practice in CA; Hepatology Fellowship at the USC Liver
    Unit and Principal Investigator or co-investigator in many clinical studies.
  • Manages over 200 patients with Hepatitis B.
  • Research focus includes liver fibrosis, drug-induced liver injury, clostridium difficile infection after liver transplants, the influence of HIV infection on chronic hepatitis B and C infection, efficacy and safety of new therapies for hepatitis B and C, and hepatitis C persistence and pathogenesis.

Interview Goal
To gain a deeper understanding of Bepirovirsen as a potential treatment for Chronic Hepatitis B

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.